The European DNA Vaccine market is anticipated to grow at a CAGR 42.3% during the forecast period. European Union is one of the unique economic and political unions between countries that together cover much of the continent. As per the International Monetary Fund, the GDP of the European Union was $19.6 trillion in 2017. As per World Bank, per capita GDP of the European Union was $39,000 in 2015with a growth of 5.5% compared to 2014. The major countries which are contributing to the DNA vaccination market are the UK, Germany, France, Italy, and Spain. The growth of the European region is backed by a significant investment on DNA vaccination by the countries.
Visit for Global DNA Vaccine Market Report at: https://www.omrglobal.com/industry-reports/dna-vaccines-market
The UK is estimated to be the dominating region in the European DNA vaccine market. Furthermore, it is also the fastest-growing region in the DNA vaccine market owing to the collaboration of the companies with Cancer Research UK for the development of a vaccine against oncology. In addition, research institutes in the country are raising funds for the development of DNA-based vaccines. Germany is estimated to be the second-largest market in the European DNA vaccine market. The government organization is much concerned about the vaccination hence due to this the coverage area of most of the countries is more than 90% for most of the diseases. Each country has its own vaccination schedule as per their environment and other factors. The UK is a major contributor in the European market.
The key market players that are active in the market include GE Healthcare, GlaxoSmithKline PLC., Merck & Co., Pfizer Inc., Sanofi Inc., Roche Diagnostics GMBH, Xenetic Biosciences Inc., Eli Lilly and Co., Novartis AG and Inovio Pharmaceuticals Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology
The market study of the European DNA Vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for Pharmaceutical companies, life science & healthcare company and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Competitive Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. European DNA Vaccine Market by Type
5.1.1. Animal DNA Vaccine
5.1.2. Human DNA Vaccine
5.2. European DNA Vaccine Market by Technology
5.2.1. Plasmid DNA Vaccine
5.2.2. Plasmid DNA Delivery
5.3. European DNA Vaccine Market by Application
5.3.1. Oncology
5.3.2. Infectious Disease
5.3.3. Others
6. Regional Analysis
6.1. European
6.1.1 United Kingdom
6.1.2 Germany
6.1.3 France
6.1.4 Italy
6.1.5 Spain
6.1.6 Rest of European
7 Company Profiles
7.1 Eli Lilly and Co.
7.2 GE Healthcare
7.3 Glaxosmithkline PLC.
7.4 Inovio Pharmaceuticals Inc.
7.5 Merck & Co.
7.6 Novartis AG
7.7 Pfizer Inc.
7.8 Roche Diagnostics GMBH
7.9 Sanofi Inc.
7.10 Xenetic Biosciences Inc.
1. EUROPEAN DNA VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
2. EUROPEAN DNA VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
3. EUROPEAN DNA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2018-2025 ($ MILLION)
4. EUROPEAN DNA VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
1. EUROPEAN DNA VACCINE MARKET SHARE BY COUNTRY, 2018 VS 2025 (%)
2. EUROPEAN DNA VACCINE MARKET SHARE BY TYPE, 2018 VS 2025 (%)
3. EUROPEAN DNA VACCINE MARKET SHARE BY TECHNOLOGY, 2018 VS 2025 (%)
4. EUROPEAN DNA VACCINE MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)
5. UK DNA VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
6. FRANCE DNA VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
7. GERMANY DNA VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
8. SPAIN DNA VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
9. ITALY DNA VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
10. REST OF EUROPE DNA VACCINE MARKET SIZE, 2018-2025 ($ MILLION)